Rhabdomyolysis events were reported per 10,000 person-years of LLD exposure; multivariate analysis was conducted.
RESULTS: The study cohort (N = 473,343) received 490,988 and 11,624 person-years of LLD, and combination therapy, respectively. Medical charts were obtained for 104 of 144 eligible patients with rhabdomyolysis claims; 42 cases were confirmed. With atorvastatin as reference, rhabdomyolysis
rates (95% confidence interval) were greatest for cerivastatin, 8 4 (2.3-21.7); no difference among available statins was observed. Rates for other LLD monotherapies were: niacin, 2.1 (0.3-7.7), ezetimibe, 2.1 (0.3-7.8), fenofibrate, 0 (0-1.7), and gemfibrozil, 2.0 (0.5-5.2). Multivariate analysis showed only cerivastatin with a significantly greater risk of rhabdomyolysis (odds ratio 4.74, 95% confidence interval 1.1-21.2, P = .041) versus atorvastatin among the statins. Combination 5-Fluoracil therapies BMS-777607 purchase had increased rhabdomyolysis risk (OR 7.1, 1.6-31.6, P = .010) versus LLDs alone.
CONCLUSION: The risk of habdomyolysis among hospitalized patients receiving statins was low; no difference among the available statins was evident. Further
data are needed to establish the risk profile but current findings already offer guidance to physicians. (C) 2013 National Lipid Association. All rights reserved.”
“Purpose of review
To provide an update on recently discovered human deafness genes and to describe advances in comprehensive genetic testing platforms for deafness, both of which have been
enabled by new massively parallel sequencing technologies.
Recent findings
Over the review period, three syndromic and six nonsyndromic Panobinostat chemical structure deafness genes have been discovered, bringing the total number of nonsyndromic deafness genes to 64. Four studies have shown the utility of massively parallel sequencing for comprehensive genetic testing for deafness. Three of these platforms have been released on a clinical or commercial basis.
Summary
Deafness is the most common sensory deficit in humans. Genetic diagnosis has traditionally been difficult due to extreme genetic heterogeneity and a lack of phenotypic variability. For these reasons, comprehensive genetic screening platforms have been developed with the use of massively parallel sequencing. These technologies are also accelerating the pace of gene discovery for deafness. Because genetic diagnosis is the basis for molecular therapies, these advances lay the foundation for the clinical care of deaf and hard-of-hearing persons in the future.”
“Introduction There is increasing awareness of the need for pedicle screw constructs in the treatment of spinal deformities in very young children. However, the long-term effects of pedicle screws on the immature spine are still unclear. We used a porcine model to analyze the morphological changes of the spinal canal and vertebral body in response to the placement of pedicle screws.
Methods 13 newborn pigs were operated on. Each pig received a single pedicle screw at the L2 level.